<DOC>
	<DOCNO>NCT02844309</DOCNO>
	<brief_summary>The purpose study evaluate efficiency oral regimen newly diagnose Waldenstr√∂m macroglobulinemia : thalidomide plus cyclophosphamide dexamethasone follow thalidomide prednisone maintenance therapy .</brief_summary>
	<brief_title>The Efficacy TCD Following TP Maintenance Therapy Newly Diagnosed WM</brief_title>
	<detailed_description>Enrolled patient accept maximum 8 cycle thalidomide plus cyclophosphamide dexamethasone . partial remission response well achieve , thalidomide plus prednisone maintenance therapy give two year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Aged &gt; =18 year 2. diagnose WM 3 . Untreated mild treat without standard regimen , especially untreated rituximab and/or bortezomib 4. symptom patient 5. lifeexpectancy 3 month . 1. diagnosed malignancy outside BNHL within one year ( include active centre neural system lymphoma ) 2 . Transformed lymphoma 3. liver renal function lesion unrelated lymphoma 4. serious complication uncontrolled diabetes , gastric ulcer serious angiocardiopathy determine physician 5 . HIV positive active HBV infection uncontrolled systematic infection 6. clinical central nervous dysfunction 7. serious surgery within 30 day 8. pregnancy baby nursing period uncontracepted childbearing period woman ; 9. allergy trail drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>